Sam Brusco, Associate Editor03.01.22
Dexcom today announced it has received U.S. Food and Drug Administration (FDA) breakthrough designation for Dexcom continuous glucose monitor (CGM) use in the hospital setting.
Dexcom’s CGM uses a small, wearable sensor and transmitter to continuously measure and send glucose levels to a smart device for real-time glucose data. The system also features customizable alerts and alarms to avoid dangerous low and high blood sugar events.
“In our extensive use of Dexcom CGM in our hospitals as part of exploratory studies over the last seven years, more than 800 of those patients treated during the pandemic, we have found that the device improves glucose control without any increased risk in hypoglycemia,” Athena Philis-Tsimikas, M.D., endocrinologist and corporate VP for the Scripps Whittier Diabetes Institute told the press. “Breakthrough Device Designation from the FDA could be transformative for using CGM for in-patient care in hospitals.”
“During the COVID-19 pandemic, the FDA allowed Dexcom CGM to be used in hospitals to help healthcare providers manage patient glucose levels,” said Gil Rivas, VP and GM of hospital at Dexcom. “What started as a response during the pandemic has shown promise as a better alternative to fingerstick blood glucose tests with greater quality of care and patient satisfaction.”
Dexcom’s CGM uses a small, wearable sensor and transmitter to continuously measure and send glucose levels to a smart device for real-time glucose data. The system also features customizable alerts and alarms to avoid dangerous low and high blood sugar events.
“In our extensive use of Dexcom CGM in our hospitals as part of exploratory studies over the last seven years, more than 800 of those patients treated during the pandemic, we have found that the device improves glucose control without any increased risk in hypoglycemia,” Athena Philis-Tsimikas, M.D., endocrinologist and corporate VP for the Scripps Whittier Diabetes Institute told the press. “Breakthrough Device Designation from the FDA could be transformative for using CGM for in-patient care in hospitals.”
“During the COVID-19 pandemic, the FDA allowed Dexcom CGM to be used in hospitals to help healthcare providers manage patient glucose levels,” said Gil Rivas, VP and GM of hospital at Dexcom. “What started as a response during the pandemic has shown promise as a better alternative to fingerstick blood glucose tests with greater quality of care and patient satisfaction.”